Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Ken, Hachimine"'
Autor:
Ken Hachimine, Masahide Kuroki, Yoshinori Nakae, Motomu Kuroki, Isao Sakata, Hirotomo Shibaguchi, Tetsushi Kinugasa, Yuichi Yamashita, Takayuki Shirakusa, Ryuji Asano, Hiromi Yamada
Publikováno v:
Cancer Science. 98:916-920
To improve the efficacy of sonodynamic therapy of cancer using photosensitizers, we developed a novel porphyrin derivative designated DCPH-P-Na(I) and investigated its photochemical characteristics and sonotoxicity on tumor cells. DCPH-P-Na(I) exhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea059e073e38b85863460026d8122182
https://doi.org/10.1111/j.1349-7006.2007.00468.x
https://doi.org/10.1111/j.1349-7006.2007.00468.x
Autor:
Hiromi Yamada, Jitian Zhang, Ken Hachimine, Masahide Kuroki, Yumiko Hirose, Adel Badran, Motomu Kuroki, Hirotomo Shibaguchi
Publikováno v:
Nihon Kikan Shokudoka Gakkai Kaiho. 55:55-64
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a455495de7388e60b6029222f85b4c0
https://doi.org/10.2468/jbes.55.55
https://doi.org/10.2468/jbes.55.55
Autor:
Tetsushi, Kinugasa, Qun, Huo, Daijiro, Higashi, Hirotomo, Shibaguchi, Motomu, Kuroki, Toshihiro, Tanaka, Kitarou, Futami, Yuichi, Yamashita, Ken, Hachimine, Shinichi, Maekawa, Kazuki, Nabeshima, Hiroshi, Iwasaki, Masahide, Kuroki
Publikováno v:
Anticancer research. 27(6A)
To understand the molecular and morphological alterations in the tight junction in colorectal cancer (CRC) tissues, the expression of eight tight junction proteins in normal and cancer colorectal tissues were compared.Adenocarcinoma tissues and paire
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::da18bc7698cddac308c6716ad9aef6eb
https://pubmed.ncbi.nlm.nih.gov/17970035
https://pubmed.ncbi.nlm.nih.gov/17970035
Autor:
Hirotomo, Shibaguchi, Nai-Xiang, Luo, Motomu, Kuroki, Jun, Zhao, Jian, Huang, Ken, Hachimine, Tetsushi, Kinugasa, Masahide, Kuroki
Publikováno v:
Anticancer research. 26(6A)
Recombinant chimeric immune receptors (CIRs) with anti-CEA specificity can retarget grafted T-cells to CEA-expressing tumors in an HLA-independent manner. To reduce the immunogenicity of conventional CIR in humans, an attempt was made to generate a C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3ac9df8763648a16de86b5d348ef6fbb
https://pubmed.ncbi.nlm.nih.gov/17195459
https://pubmed.ncbi.nlm.nih.gov/17195459
Autor:
Masahide, Kuroki, Jian, Huang, Hirotomo, Shibaguchi, Toshihiro, Tanaka, Jun, Zhao, Naixiang, Luo, Ken, Hachimine, Tetsushi, Kinugasa, Shin-Ichi, Maekawa, Sotaro, Enatsu, Wakako, Hamanaka, Tatsuya, Fukami, Motomu, Kuroki
Publikováno v:
Anticancer research. 26(6A)
In this review article the possible applications of anti-tumor-associated antigen (TAA) antibodies in the therapy of cancer have been summarized. First, recombinant monoclonal antibodies (MAbs) are increasingly being used as therapeutic agents, espec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c68bb3fc68b9d3befd2279bcc0dee7ab
https://pubmed.ncbi.nlm.nih.gov/17195452
https://pubmed.ncbi.nlm.nih.gov/17195452
Autor:
Masahide, Kuroki, Ken, Hachimine, Jian, Huang, Hirotomo, Shibaguchi, Tetsushi, Kinugasa, Shin-Ichi, Maekawa, Motomu, Kuroki
Publikováno v:
Anticancer research. 25(6A)
Cellular immunity, in which cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are main effector cells, plays an important role in the antitumor defense mechanism. T cell immunotherapy is based on the assumption that tumor antigen (TA) pept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f1488e7a81d70ff8f098a12476fe4ddf
https://pubmed.ncbi.nlm.nih.gov/16302732
https://pubmed.ncbi.nlm.nih.gov/16302732
Autor:
Hirotomo, Shibaguchi, Masahide, Kuroki, Motomu, Kuroki, Adel, Badran, Ken, Hachimine, Tetsushi, Kinugasa
Publikováno v:
Anticancer research. 24(5C)
Taking into consideration immunogenicity in humans, human antibodies and their derivatives have potential advantages for cancer immunotherapy and/or gene therapy over those from different species such as mouse. Recently, we generated 22 human monoclo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7bb0c172f40f5fd8d4708b51c75903b2
https://pubmed.ncbi.nlm.nih.gov/15515431
https://pubmed.ncbi.nlm.nih.gov/15515431
Autor:
Masahide, Kuroki, Motomu, Kuroki, Hirotomo, Shibaguchi, Ken, Hachimine, Tetsushi, Kinugasa, Adel, Badran
Publikováno v:
Anticancer research. 24(5C)
Gene therapy is a promising modality for the treatment of malignant tumors for which conventional therapies are often inadequate. Various therapeutic genes have shown promise for tumor cell killing. However, successful gene therapy depends on the dev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::15c11f7c9522abe4177f186ff6ead0fe
https://pubmed.ncbi.nlm.nih.gov/15515434
https://pubmed.ncbi.nlm.nih.gov/15515434
Autor:
Adel Badran, Hirotomo Shibaguchi, Ken Hachimine, Tetsushi Kinugasa, Jitian Zhang, Masahide Kuroki, Motomu Kuroki
Publikováno v:
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 25(4)
Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are main effecter cells in cellular immunity against tumor cells. T-cell immunotherapy is based on the assumption that tumor(-associated) antigen (TA) peptides are correctly presented by HL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3c94ea85f0ae9fb50fb67d91aebab9b
https://pubmed.ncbi.nlm.nih.gov/15557759
https://pubmed.ncbi.nlm.nih.gov/15557759